Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Goldenwell Biotech (GWLL) Operating Expenses (2019 - 2025)

Goldenwell Biotech (GWLL) has disclosed Operating Expenses for 7 consecutive years, with $30885.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Operating Expenses rose 47.32% year-over-year to $30885.0, compared with a TTM value of $122832.0 through Sep 2025, up 4.83%, and an annual FY2024 reading of $123162.0, up 5.73% over the prior year.
  • Operating Expenses was $30885.0 for Q3 2025 at Goldenwell Biotech, down from $40619.0 in the prior quarter.
  • Across five years, Operating Expenses topped out at $920332.0 in Q4 2022 and bottomed at -$150479.0 in Q4 2021.
  • Average Operating Expenses over 5 years is $60638.8, with a median of $28751.0 recorded in 2022.
  • Peak annual rise in Operating Expenses hit 10658.37% in 2021, while the deepest fall reached 5149.63% in 2021.
  • Year by year, Operating Expenses stood at -$150479.0 in 2021, then surged by 711.6% to $920332.0 in 2022, then plummeted by 97.9% to $19361.0 in 2023, then dropped by 1.6% to $19051.0 in 2024, then skyrocketed by 62.12% to $30885.0 in 2025.
  • Business Quant data shows Operating Expenses for GWLL at $30885.0 in Q3 2025, $40619.0 in Q2 2025, and $32277.0 in Q1 2025.